PortViewPortView
NuVasive logo

NuVasive (NUVA) Stock Analysis

NASDAQHealthcareMedical - Devices

$39.75-2.24%
1-year price historyRange $35.68 – $49.34
52-week range$39.75
$35.17$49.53

What NuVasive does

NuVasive, Inc. is a medical technology firm focused on creating, producing, and distributing comprehensive procedural solutions for spinal operations. The company offers a range of surgical access instruments, such as the Maxcess integrated split-blade retractor system, which facilitates less-invasive surgical approaches by significantly reducing soft tissue disruption during spinal procedures. Additionally, NuVasive manufactures specialized spinal implants designed to improve spinal fusion by optimizing the osseointegration and biomechanical characteristics of materials like porous titanium and porous polyetheretherketone. Its fixation systems are engineered to help maintain and re-establish proper patient alignment. Other offerings include cervical total disc replacement technology, used in cervical spinal fusion surgery, and advanced neuromonitoring systems. These systems leverage proprietary software for nerve detection and avoidance, complemented by comprehensive intraoperative neuromonitoring services and support. The Pulse platform, a distinctive software ecosystem, unifies various hardware technologies into a compact, integrated system within the operating room environment. Furthermore, NuVasive supplies expandable growing rod implant systems for managing early-onset scoliosis, along with diverse biologics crucial for supporting spinal fusion or bone healing. Another key product is Precice, an intramedullary implant device that employs MAGEC technology for the non-invasive lengthening of the femur and tibia. The company also offers both onsite and remote monitoring solutions for the neurological systems of patients undergoing spinal and brain-related surgical interventions. NuVasive distributes its products to a broad client base, including patients, surgeons, hospitals, and insurers, through a multi-channel sales approach encompassing independent sales agents, its own sales force, and distributors, operating across the United States and global markets. Established in 1997, NuVasive, Inc. maintains its corporate headquarters in San Diego, California.

Key metrics

Market cap
$2.08B
P/E (TTM)
75.00
EPS (TTM)
$0.53
Beta
1.07
Dividend yield
0.00%
Revenue / share
$20.95
50-day avg
$40.83
200-day avg
$41.23
52-week high
$49.53
52-week low
$35.17
CEO
J. Christopher Barry

ETFs linked to NUVA

Broad-market and Healthcare sector ETFs an investor holding NuVasive is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NUVA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze NUVA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for NuVasive?
NuVasive trades under the ticker NUVA on NASDAQ.
Which exchange is NUVA listed on?
NUVA is listed on NASDAQ.
What sector does NuVasive operate in?
NuVasive is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze NUVA in a portfolio?
PortView shows NUVA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.